Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomepromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.50 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.98 |
| ▸ | HTR1A | P08908 | 6/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.98 |
| ▸ | DRD1 | P21728 | 5/20 | 0.98 |
| ▸ | LMNA | P02545 | 4/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomepromazine SCHEMBL1611636 | 1.00 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29846205 | 1.00 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29425180 | 0.99 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL6944555 | 0.99 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL30411640 | 0.99 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL23859840 | 0.99 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29384983 | 0.99 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL8762418 | 0.99 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL25462 | 0.99 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29508092 | 0.99 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 607 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| US-8524665-B2 | Use of secretin in treatments of disorders associated with the amygdala | THE MCLEAN HOSPITAL CORPORATION (US) | 2013-09-03 | — | — | US | claimed |
| WO-2007092432-A2 | LIQUID-FILLED NANODROPLETS FOR ANTI-CANCER THERAPY | IMARX THERAPEUTICS, INC. (US) | 2007-08-16 | — | — | WO | claimed |
| US-20070185018-A1 | Use of secretin in treatments of disorders associated with the amygdala | THE MCLEAN HOSPITAL CORPORATION | 2007-08-09 | — | — | US | claimed |
| US-20070184076-A1 | Liquid-filled nanodroplets for anti-cancer therapy | IMA RY THERAPEUTICS, INC. | 2007-08-09 | — | — | US | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| US-20050176650-A1 | Stable parenteral formulation of levomepromazine and a method for stabilizing said formulation | XANODYNE PHARMACAL, INC. (US) | 2005-08-11 | — | — | US | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| WO-2004100899-A2 | USE OF SECRETIN IN TREATMENTS OF DISORDERS ASSOCIATED WITH THE AMYGDALA | THE MCLEAN HOSPITAL CORPORATION (US) | 2004-11-25 | — | — | WO | claimed |
| US-20030198664-A1 | Lipid mediated screening of drug candidates for identification of active compounds | FLORIDA, UNIVERSITY OF | 2003-10-23 | — | — | US | claimed |
| WO-2003083443-A2 | LIPID MEDIATED SCREENING OF DRUG CANDIDATES FOR IDENTIFICATION OF ACTIVE COMPOUNDS | UNIVERSITY OF FLORIDA (US) | 2003-10-09 | — | — | WO | claimed |
| US-20030147812-A1 | Device and methods for initiating chemical reactions and for the targeted delivery of drugs or other agents | DORNIER MEDTECH SYSTEMS GMBH. (DE) | 2003-08-07 | — | — | US | claimed |
| EP-0983060-A4 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2002-04-24 | — | — | EP | claimed |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX THERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| EP-0983060-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998051282-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | claimed |
| US-5770222-A | Therapeutic drug delivery systems | IMARX PHARMACEUTICAL CORP. (US) | 1998-06-23 | — | — | US | claimed |
| EP-0180364-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1990-03-07 | — | — | EP | claimed |
| EP-0180364-A2 | Pharmaceutical compositions containing phenothiazines | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1986-05-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | EXOSC9, EXOSC5, EXOSC4 | DRD3 2487/4885DRD2 2359/4885DRD4 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.